<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02603835</url>
  </required_header>
  <id_info>
    <org_study_id>IDE G120029/S007</org_study_id>
    <nct_id>NCT02603835</nct_id>
  </id_info>
  <brief_title>Evaluation of Intracoronary Hyperoxemic Oxygen Therapy in Anterior Acute Myocardial Infarction Patients (IC-HOT)</brief_title>
  <acronym>IC-HOT</acronym>
  <official_title>A Multi-Center Evaluation of the Delivery of Intracoronary Hyperoxemic Supersaturated Oxygen Therapy for 60 Minutes in Anterior Acute Myocardial Infarction Patients With Successful Reperfusion (Via PCI) ≤ Six Hours After Symptom Onset</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TherOx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TherOx</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to collect confirmatory data supporting the safety and&#xD;
      effectiveness of SSO2 Therapy in treatment of anterior acute myocardial infarction (AMI)&#xD;
      patients who have undergone successful percutaneous coronary intervention (PCI) with stenting&#xD;
      within six hours of experiencing AMI symptoms.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Multi-Center, Consecutively Enrolled Single-Arm Study to confirm the safety and&#xD;
      effectiveness of the delivery of supersaturated oxygen (SSO2) Therapy for 60 minutes&#xD;
      selectively into the left main coronary artery (LMCA) with a commercially available qualified&#xD;
      SSO2 delivery catheter used with the TherOx® DownStream® System and Cartridge in the&#xD;
      treatment of qualified patients presenting with anterior acute myocardial infarction in whom&#xD;
      reperfusion with PCI is successful within six hours after symptom onset.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">February 2016</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Actual">August 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Net Adverse Clinical Events (NACE)</measure>
    <time_frame>30-Day</time_frame>
    <description>Composite of death, reinfarction, clinically-driven target vessel revascularization, stent thrombosis (ARC definite or probable), new onset severe heart failure or readmission for heart failure, and TIMI major or minor bleeding</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Anterior Wall Acute Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>SSO2 Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Delivery of SSO2 Therapy for 60 minutes selectively into the left main coronary artery (LMCA) using the TherOx DownStream System along with a single use disposable device called the TherOx DownStream Cartridge and a commercially available, qualified SSO2 delivery catheter</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SSO2 Therapy</intervention_name>
    <description>Delivery of SSO2 Therapy for 60 minutes selectively into the left main coronary artery (LMCA) using the TherOx DownStream System along with a single use disposable device called the TherOx DownStream Cartridge and a commercially available, qualified SSO2 delivery catheter</description>
    <arm_group_label>SSO2 Therapy</arm_group_label>
    <other_name>TherOx DownStream System</other_name>
    <other_name>TherOx DownStream Cartridge</other_name>
    <other_name>SSO2 Delivery Catheter</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        GENERAL INCLUSION CRITERIA: Candidates for this study must meet ALL of the following&#xD;
        criteria:&#xD;
&#xD;
        Pre-PCI:&#xD;
&#xD;
          1. The subject must be ≥18 and ≤80 years of age.&#xD;
&#xD;
          2. AMI must be anterior (ST-segment elevation &gt;1 mm in two or more contiguous leads&#xD;
             between V1 and V4 or new left bundle branch block).&#xD;
&#xD;
          3. Subject is experiencing clinical symptoms consistent with anterior AMI of ≤6 hour&#xD;
             duration from time of symptom onset until admission to the emergency room.&#xD;
&#xD;
          4. The subject or legally authorized representative has been informed of the nature of&#xD;
             the study, agrees to its provisions and has been provided and signed written informed&#xD;
             consent, approved by the appropriate Institutional Review Board (IRB).&#xD;
&#xD;
          5. Subject and his/her physician agree to all required follow-up procedures and visits.&#xD;
&#xD;
             ANGIOGRAPHIC INCLUSION CRITERIA: These are evaluated after the subject has provided&#xD;
             signed informed consent but prior to enrollment:&#xD;
&#xD;
          6. Based on coronary anatomy, PCI is indicated for revascularization of the culprit&#xD;
             lesion(s) with use of a commercially available coronary stent (bare metal or&#xD;
             drug-eluting, at operator discretion) in the LAD.&#xD;
&#xD;
          7. The primary stented infarct-related lesion(s) must be in the proximal and/or mid-LAD&#xD;
             coronary artery (other lesions in the LAD target vessel, including diagonal branches,&#xD;
             may be treated if clinically indicated).&#xD;
&#xD;
          8. Baseline (pre-PCI) TIMI flow grade 0, 1, 2, or 3 flow in the LAD.&#xD;
&#xD;
          9. Successful angioplasty as documented by &lt;50% diameter residual angiographic stenosis&#xD;
             within all treated culprit lesions with TIMI 2 or 3 flow and no major complications&#xD;
             such as perforation or shock.&#xD;
&#xD;
         10. Expected ability to place the SSO2 delivery catheter in the coronary ostium of the&#xD;
             left main coronary system to deliver SSO2 Therapy with stable, coaxial alignment.&#xD;
&#xD;
        GENERAL EXCLUSION CRITERIA:&#xD;
&#xD;
        Pre-PCI:&#xD;
&#xD;
          1. Prior CABG surgery.&#xD;
&#xD;
          2. Prior myocardial infarction, or known prior systolic dysfunction (known ejection&#xD;
             fraction &lt;40% by any prior measure or regional wall motion abnormalities; this&#xD;
             criterion does not include left ventricular dysfunction induced by the acute MI).&#xD;
&#xD;
          3. Thrombolytic therapy administered for this STEMI.&#xD;
&#xD;
          4. An elective surgical procedure is planned that would necessitate interruption of&#xD;
             anti-platelet agents during the first 30 days post-enrollment.&#xD;
&#xD;
          5. Subjects who previously underwent coronary stent implantation and in whom coronary&#xD;
             angiography demonstrates stent thrombosis to be the cause of the anterior AMI.&#xD;
&#xD;
          6. Subjects who have previously undergone an angioplasty or stenting procedure in the&#xD;
             left anterior descending coronary artery.&#xD;
&#xD;
          7. Subjects with ventricular pseudoaneurysm, VSD, or severe mitral valve regurgitation&#xD;
             (with or without papillary muscle rupture).&#xD;
&#xD;
          8. Any contraindication to MRI imaging. This will include any of the following&#xD;
             exclusions:&#xD;
&#xD;
               -  Cardiac pacemaker or implantable defibrillator;&#xD;
&#xD;
               -  Non-MRI compatible aneurysm clip;&#xD;
&#xD;
               -  Neural Stimulator (i.e., TENS unit);&#xD;
&#xD;
               -  Any implanted or magnetically activated device (insulin pump);&#xD;
&#xD;
               -  Any type of non-MRI compatible ear implant;&#xD;
&#xD;
               -  Metal shavings in the orbits;&#xD;
&#xD;
               -  Any metallic foreign body, shrapnel, or bullet in a location which the physician&#xD;
                  feels would present a risk to the subject;&#xD;
&#xD;
               -  Any history indicating contraindication to MRI, including claustrophobia or&#xD;
                  allergy to gadolinium;&#xD;
&#xD;
               -  Inability to follow breath hold instructions or to maintain a breath hold for &gt;15&#xD;
                  seconds; and&#xD;
&#xD;
               -  Known hypersensitivity or contraindication to gadolinium contrast.&#xD;
&#xD;
          9. Known impaired renal function (creatinine clearance &lt;30 ml/min/1.73 m2&#xD;
&#xD;
         10. Known platelet count &lt;100,000 cells/mm by the MDRD formula) or on dialysis. 3 or&#xD;
             &gt;700,000 cells/mm3&#xD;
&#xD;
         11. Subject has active bleeding or a history of bleeding diathesis or coagulopathy&#xD;
             (including heparin induced thrombocytopenia), or refusal to receive blood transfusions&#xD;
             if necessary. or a known Hgb &lt;10 g/dL.&#xD;
&#xD;
         12. History of intracerebral mass, aneurysm, arteriovenous malformation, or hemorrhagic&#xD;
             stroke.&#xD;
&#xD;
         13. Stroke or transient ischemic attack within the past six (6) months, or any permanent&#xD;
             neurological defect.&#xD;
&#xD;
         14. Gastrointestinal or genitourinary bleeding within the last two (2) months, or any&#xD;
             major surgery (including CABG) within six weeks of enrollment.&#xD;
&#xD;
         15. Subject has received any organ transplant or is on a waiting list for any organ&#xD;
             transplant.&#xD;
&#xD;
         16. Subject has other medical illness (e.g., cancer, dementia) or known history of&#xD;
             substance abuse (alcohol, cocaine, heroin, etc.) that may cause non-compliance with&#xD;
             the protocol, confound the data interpretation, or is associated with limited life&#xD;
             expectancy of less than one year.&#xD;
&#xD;
         17. Subject has a known hypersensitivity or contraindication to unfractionated heparin,&#xD;
             abciximab, aspirin, bivalirudin, cangrelor, clopidogrel, ticlopidine, prasugrel, or&#xD;
             ticagrelor that cannot be adequately premeditated.&#xD;
&#xD;
         18. Current use of warfarin, dabigatran, or factor Xa inhibitors, or known intent to&#xD;
             administer these agents after the primary PCI.&#xD;
&#xD;
         19. Subjects presenting with or developing in the cath lab prior to completion of the&#xD;
             primary PCI procedure any of the following conditions: cardiogenic shock (SBP &lt;80 mmHg&#xD;
             for &gt;30 minutes), or requiring IV pressors or emergent placement of an intra-aortic&#xD;
             balloon pump (IABP), Impella, or other hemodynamic support for hypotension treatment,&#xD;
             or cardiopulmonary resuscitation for &gt;10 minutes, or ventricular fibrillation or&#xD;
             tachycardia requiring cardioversion or defibrillation.&#xD;
&#xD;
         20. Severe known cardiac valvular stenosis or insufficiency, pericardial disease, or&#xD;
             non-ischemic cardiomyopathy.&#xD;
&#xD;
         21. Any significant medical or social condition which in the investigator's opinion may&#xD;
             interfere with the subject's participation in the study or ability to comply with&#xD;
             follow-up procedures, including MRI (e.g. alcoholism, dementia, lives far from the&#xD;
             research center, etc.).&#xD;
&#xD;
         22. Current participation in other investigational device or drug trials that have not&#xD;
             finished the primary endpoint follow-up period.&#xD;
&#xD;
         23. Previous enrollment in this study.&#xD;
&#xD;
             ANGIOGRAPHIC EXCLUSION CRITERIA: These are evaluated after the subject has provided&#xD;
             signed Informed Consent but prior to enrollment:&#xD;
&#xD;
         24. Anticipated inability to achieve a stable coaxial position in the left main coronary&#xD;
             artery with the SSO2 delivery catheter.&#xD;
&#xD;
         25. Treatment during the index procedure of any lesion in either the left main, LCX&#xD;
             (including the ramus), and/or RCA.&#xD;
&#xD;
         26. Post-index procedure planned intervention within 30 days (i.e., PCI of non-target&#xD;
             lesions in any vessel, or CABG). Note: Planned revascularization (PCI or bypass) of a&#xD;
             non-target lesion &gt;30 days following the index procedure is allowed.&#xD;
&#xD;
         27. Anterior MI is due to thrombosis within or adjacent to a previously implanted stent.&#xD;
&#xD;
         28. Left ventriculography demonstrates severe mitral regurgitation, a ventricular septal&#xD;
             defect, or a pseudoaneurysm.&#xD;
&#xD;
         29. Any left main coronary artery stenosis &gt;20%.&#xD;
&#xD;
         30. Any untreated LAD or diagonal branch lesion is present with diameter stenosis &gt; 50% in&#xD;
             a vessel with reference vessel diameter &gt; 2.0 mm (visually estimated), or for which&#xD;
             PCI will be required before the MRI study.&#xD;
&#xD;
         31. Presence of a non-stented coronary dissection with NHLBI grade &gt;B upon completion of&#xD;
             the PCI procedure.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregg W. Stone, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Heart Center, Inc.</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scripps Hospital</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Danbury Hospital</name>
      <address>
        <city>Danbury</city>
        <state>Connecticut</state>
        <zip>06801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alexian Brothers Heart &amp; Vascular Institute</name>
      <address>
        <city>Elk Grove Village</city>
        <state>Illinois</state>
        <zip>60007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baystate Medical Center</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01199</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Medical Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. John Hospital &amp; Medical Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beaumont Hospital</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence-Providence Park Hospital</name>
      <address>
        <city>Southfield</city>
        <state>Michigan</state>
        <zip>48075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>WakeMed Heart Center</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lehigh Valley Hospital</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holy Spirit Cardiology</name>
      <address>
        <city>Camp Hill</city>
        <state>Pennsylvania</state>
        <zip>17011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geisinger Medical Center</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Miriam Hospital/Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wellmont CVA Heart Institute</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <study_first_submitted>November 10, 2015</study_first_submitted>
  <study_first_submitted_qc>November 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2015</study_first_posted>
  <last_update_submitted>September 22, 2017</last_update_submitted>
  <last_update_submitted_qc>September 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SSO2 Therapy</keyword>
  <keyword>Acute myocardial infarction</keyword>
  <keyword>Anterior myocardial infarction</keyword>
  <keyword>SuperSaturated oxygen delivery</keyword>
  <keyword>Left main coronary artery</keyword>
  <keyword>Myocardial infarction</keyword>
  <keyword>Heart attack</keyword>
  <keyword>Percutaneous coronary intervention</keyword>
  <keyword>Cardiac catheterization laboratory</keyword>
  <keyword>PCI</keyword>
  <keyword>Stent</keyword>
  <keyword>Stenting</keyword>
  <keyword>Stents</keyword>
  <keyword>Angioplasty</keyword>
  <keyword>LMCA</keyword>
  <keyword>Delivery of supersaturated oxygen (SSO2) therapy for the treatment of anterior acute myocardial infarction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

